Milestone Pharmaceuticals Inc. Common Shares (MIST)
Stock · NASDAQ · Health Care
$0.7071as of 10/16/2026
Price chart
Active signals
MIST Signal Track Record
How signals performed across all stocks →What MIST's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -5.1% | 37% | September 3, 2026 |
| Bollinger Band Breakdown | 22 | -4.5% | 45% | September 11, 2026 |
| Bollinger Band Breakout | 18 | -5.9% | 44% | November 17, 2025 |
| 200-Day Moving Average TouchActive now | 11 | +13.1% | 55% | May 7, 2026 |
| Any 20-session window (baseline) | -2.3% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the ind…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 38
- Website
- www.milestonepharma.com
Fundamentals
- 1-day range
- $0.704$0.8
- Market cap
- $146.91M
- P/E (trailing)
- —
- P/E (forward)
- -0.92
- EPS (trailing)
- $-0.69
- Dividend yield
- —
- Beta
- 1.05
- Avg. volume
- 1.42M
Forecasts
7 analyst ratings
Milestone Pharmaceuticals Inc. Common Shares Competitors
Chosen by industry and closest market cap.
- MISTMilestone Pharmaceuticals Inc. Common Shares$0.707▼ 11.07%Market cap $146.91MP/E —$0.7075$3.06
- ADCTADC Therapeutics SA Common Shares$1.4▼ 6.04%Market cap $143.73MP/E —$0.7796$4.98
- CNTNCanton Strategic Holdings Inc. Common Stock$1.7▼ 9.36%Market cap $143.45MP/E —$1.75$6.89
- NGENNervGen Pharma Corp. Common stock$1.59▼ 1.85%Market cap $141.37MP/E —$3.2$8.49
- KZIAKazia Therapeutics Limited American Depositary Shares$7.25▼ 2.03%Market cap $140.89MP/E —$4.86$17.4
- MENSJyong Biotech Ltd. Ordinary Shares$1.84▼ 7.07%Market cap $153.58MP/E —$1.43$63
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MIST Milestone Pharmaceuticals Inc. Common Shares | $146.91M | — | $0.707 | ▼ 11.07% | $0.7075$3.06 |
| ADCT ADC Therapeutics SA Common Shares | $143.73M | — | $1.4 | ▼ 6.04% | $0.7796$4.98 |
| CNTN Canton Strategic Holdings Inc. Common Stock | $143.45M | — | $1.7 | ▼ 9.36% | $1.75$6.89 |
| NGEN NervGen Pharma Corp. Common stock | $141.37M | — | $1.59 | ▼ 1.85% | $3.2$8.49 |
| KZIA Kazia Therapeutics Limited American Depositary Shares | $140.89M | — | $7.25 | ▼ 2.03% | $4.86$17.4 |
| MENS Jyong Biotech Ltd. Ordinary Shares | $153.58M | — | $1.84 | ▼ 7.07% | $1.43$63 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Duty Stuart · June 10, 2026 · Grant77.0K
- Robert James Wills · June 10, 2026 · Grant77.0K
- Saik Andrew · June 10, 2026 · Grant77.0K
- Fischer Seth H. Z. · June 10, 2026 · Grant77.0K
- Michael John Tomsicek · June 10, 2026 · Grant77.0K
- Lisa M. Giles · June 10, 2026 · Grant77.0K
- Joseph C. Papa · June 10, 2026 · Grant77.0K
- Joseph Oliveto · April 16, 2026 · Sale36.5K @ $2.26
Institutional Ownership
March 31, 2026
- Total shares held
- 30.09M
- Total value held
- $35.73M
- Institutional holders
- 84
- Unknown6.33M
- Unknown4.12M
- Unknown2.32M
- Unknown2.00M
- Unknown1.94M
- Unknown1.54M
- Unknown1.51M
- Unknown1.09M
- Unknown851.3K
- Unknown820.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial
Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial. Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.